Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 1

Status

Withdrawn 1Terminated 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Genitourinary 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 699Lung Neoplasms 297Small Cell Lung Carcinoma 149Colorectal Neoplasms 113Melanoma 106Neoplasms 93Breast Neoplasms 93Ovarian Neoplasms 92Neoplasm Metastasis 85Squamous Cell Carcinoma of Head and Neck 83Stomach Neoplasms 81Pancreatic Neoplasms 78Carcinoma, Renal Cell 66Triple Negative Breast Neoplasms 63Esophageal Neoplasms 51Endometrial Neoplasms 48Uterine Cervical Neoplasms 47Head and Neck Neoplasms 47Mesothelioma 42Mesothelioma, Malignant 41Sarcoma 40Prostatic Neoplasms 36Urinary Bladder Neoplasms 34Carcinoma, Transitional Cell 32Colonic Neoplasms 31Carcinoma, Hepatocellular 31Adenocarcinoma of Lung 31Carcinoma 26Recurrence 21Thyroid Neoplasms 20

Interventions

pembrolizumab 1bintrafusp alfa protein, human 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Camurati-Engelmann Syndrome × Thoracic × Clear all
NCT04297748 2023-01-17

Bioimaging Study of 89Zr-M7824 in NSCLC

Olivia Newton-John Cancer Research Institute

Phase 1/2 Terminated
5 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Camurati-Engelmann Syndrome

NCT04158700 2020-02-19

A Study of LY3200882 and Pembrolizumab in Participants With Advanced Cancer

Eli Lilly and Company

Phase 1/2 Withdrawn
GastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Camurati-Engelmann Syndrome, Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡